Chemical-structure (Chemical Structure)
Tofacitinib Citrate Tablet, Film Coated, Extended Release
Product Images NDC 0574-1811
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tofacitinib Citrate (NDC 0574-1811). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Padagis Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-1 (Figure 1)
This text mentions renal impairment and hepatic impairment, with varying degrees of severity. It also refers to ratio and 90% confidence interval values. The information seems to be related to the impact of renal and hepatic impairments on certain parameters or outcomes.*
Figure-2 (Figure 2)
This text provides information on the coadministration of various drugs and their PK ratio and 90% CI values. It includes drugs like Methotrexale, Midazolam, Levonorgestrel, Ethinyl Estradiol, Metformin, and the respective parameters like cmax and AUC. The text also features a table with ratio values relative to a reference.*
Figure-3 (Figure 3)
Figure-4 (Figure 4)
Figure-5 (Figure 5)
Figure-6 (Figure 6)
Label (Label)
This is a description of Tofacitinib Extended-Release Tablets, each tablet contains 1mg of Tofacitinib Citrate. It is recommended to dispense the accompanying Medication Guide to each patient. The tablets should be stored at 20°C to 25°C (68°F to 77°F). The manufacturer is Padagis®, with the tablets being manufactured by Haimen Pharma Inc. in China. The dosage and usage instructions can be found in the accompanying prescribing information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
